Bernard Taverne, Alice Desclaux, Papa Salif Sow

More documents

Recommendations

Info

CHAPITRE II-4L'observance au traitement, tendance à long terme42. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highlyactive antiretroviral therapy assessed by pharmacy claims predictssurvival in HIV-infected South African adults. J Acquir ImmuneDefic Syndr. Sep 2006;43(1):78-84.43. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviraltherapy at primary care sites in Zambia: feasibility and early outcomes.Jama. Aug 16 2006;296(7):782-793.44. Crane JT, Kawuma A, Oyugi JH, et al. The price of adherence:qualitative findings from HIV positive individuals purchasing fixeddosecombination generic HIV antiretroviral therapy in Kampala,Uganda. AIDS Behav. Jul 2006;10(4):437-442.45. Nwauche C, Erhabor O, Ejele O, Akani C. Adherence to antiretroviraltherapy among HIV-infected subjects in a resource - limitedsetting in the Niger Delta of Nigeria. African Journal of HealthSciences. 2006;13:13-17.46. Rosen S, Ketlhapile M, Sanne I, DeSilva MB. Cost to patientsof obtaining treatment for HIV/AIDS in South Africa. S Afr Med J.Jul 2007;97(7):524-529.ird-00718213, version 1 - 16 Jul 201247. Wakabi W. Low ART adherence in Africa. Lancet Infect Dis.Feb 2008;8(2):94.48. Costagliola D, Barberousse C. Comment mesurer l'observance?In: Bessette D, Bungener M, Costagliola D, Flori YA,Matheron S, Morin M, Setbon M, Souteyrand Y, editors.L’observance aux traitements contre le VIH/sida: mesure, déterminants,évolution. Collection sciences sociales et sida. Paris:ANRS, 2002 ;33–42.49. Farmer KC. Methods for measuring and monitoring medicationregimen adherence in clinical trials and clinical practice. Clin Ther.Jun 1999;21(6):1074-1090; discussion 1073.50. Stone VE. Strategies for optimizing adherence to highly activeantiretroviral therapy: lessons from research and clinical practice.Clin Infect Dis. Sep 15 2001;33(6):865-872.51. De Beaudrap P, Etard JF, Ecochard R, et al. Change over timeof mortality predictors after HAART initiation in a Senegalesecohort. Eur J Epidemiol. 2008;23(3):227-234.99
CHAPITRE II-4L'observance au traitement, tendance à long termeTABLEAU 1CARACTÉRISTIQUES À L’INCLUSION DES PATIENTS DE LA COHORTE INITIALEET DES PATIENTS DE LA COHORTE INCLUS EN MAI 2004, SÉNÉGAL, 1998-2010.ird-00718213, version 1 - 16 Jul 2012TABLEAU 2Characteristics Original cohort Included in Overall(n=158) May 2004 (n=171) p (n=329)Agemedian [IQR] 38 [32 – 43] 37 [30 – 43] 0.42 37 [31 – 43]Gender n(%)Men 79 (50.0) 67 (39.2) 146 (44.4)Women 79 (50.0) 104 (60.8) 0.03 183 (55.6)CD4 (cells/μL)median [IQR] 136 [61 – 217] 145 [57 – 228] 0.91 139 [59 – 221]< 50 35 (22.3) 38 (23.0) 73 (22.7)50 – 199 73 (46.5) 70 (42.4) 143 (44.4)200 – 349 38 (24.2) 49 (29.7) 87 (27.0)≥ 350 11 (7.0) 8 (4.9) 19 (5.9)Viral load (log10 cp/mL)median [IQR] 5.3 [4.8 – 5.7] 5.0 [4.6 – 5.4]
Page 1 and 2:
ird-00718213, version 1 - 16 Jul 20
Page 3 and 4:
ird-00718213, version 1 - 16 Jul 20
Page 5 and 6:
ird-00718213, version 1 - 16 Jul 20
Page 7 and 8:
Evaluation de l’impact bio-cliniq
Page 9 and 10:
ird-00718213, version 1 - 16 Jul 20
Page 11 and 12:
Page 13 and 14:
ird-00718213, version 1 - 16 Jul 20
Page 15 and 16:
ird-00718213, version 1 - 16 Jul 20
Page 17 and 18:
CHAPITRE I-1Mortalité : incidence,
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
ird-00718213, version 1 - 16 Jul 20
Page 31 and 32:
CHAPITRE I-2Réponse immuno-virolog
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
ird-00718213, version 1 - 16 Jul 20
Page 41 and 42:
CHAPITRE I-3Evénements indésirabl
Page 43 and 44:
CHAPITRE I-3Evénements indésirabl
Page 45 and 46:
ird-00718213, version 1 - 16 Jul 20
Page 47 and 48:
CHAPITRE I-4Vieillissement accélé
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58: CHAPITRE I-4Vieillissement accélé
Page 65 and 66: ird-00718213, version 1 - 16 Jul 20
Page 67 and 68: CHAPITRE II-1Diabète et hypertensi
Page 79 and 80: CHAPITRE II-2Lipodystrophies : pré
Page 91 and 92: CHAPITRE II-3Santé sexuelle : étu
Page 103 and 104: CHAPITRE II-4L'observance au traite
Page 105 and 106: CHAPITRE II-4L'observance au traite
Page 107: CHAPITRE II-4L'observance au traite
Page 115 and 116: CHAPITRE III-1De l’expérience de
Page 127 and 128: CHAPITRE III-2Lipodystrophies : per
Page 155 and 156: CHAPITRE III-3Perception du risque
Page 157 and 158: CHAPITRE III-3Perception du risque
Page 159 and 160:
CHAPITRE III-3Perception du risque
Page 161 and 162:
CHAPITRE III-3Perception du risque
Page 163 and 164:
CHAPITRE III-4 Les plaintes et leur
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
CHAPITRE III-5 Typologie de l’exp
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
ird-00718213, version 1 - 16 Jul 20
Page 191 and 192:
ird-00718213, version 1 - 16 Jul 20
Page 193 and 194:
CHAPITRE IV-1Le devenir socio-écon
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
CHAPITRE IV-2Le partage du statut s
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
ird-00718213, version 1 - 16 Jul 20
Page 229 and 230:
CHAPITRE IV-3Le partage de l’info
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
ird-00718213, version 1 - 16 Jul 20
Page 239 and 240:
CHAPITRE IV-4Les attitudes en mati
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
ird-00718213, version 1 - 16 Jul 20
Page 253 and 254:
CHAPITRE VI-5Le mariage, entre souh
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
ird-00718213, version 1 - 16 Jul 20
Page 265 and 266:
CHAPITRE IV-6L’expérience du veu
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
CHAPITRE IV-7Les personnes âgées
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
ird-00718213, version 1 - 16 Jul 20
Page 307 and 308:
CHAPITRE V-1Perceptions et prise en
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
ird-00718213, version 1 - 16 Jul 20
Page 319 and 320:
CHAPITRE V-2Dispositif institutionn
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
ird-00718213, version 1 - 16 Jul 20
Page 329 and 330:
CHAPITRE V-3Evolution des coûts ho
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
CHAPITRE V-4Du patient au réseau :
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
CHAPITRE V-5Dispositif expérimenta
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
ird-00718213, version 1 - 16 Jul 20
Page 391 and 392:
CHAPITRE V-6Mesurer la stigmatisati
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
ird-00718213, version 1 - 16 Jul 20
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
ird-00718213, version 1 - 16 Jul 20
Page 419 and 420:
ird-00718213, version 1 - 16 Jul 20
Page 421 and 422:
Dans le cadre de cette cohorte, une
Page 423 and 424:
propriété intellectuelle et la co
Page 425 and 426:
ird-00718213, version 1 - 16 Jul 20
Page 427 and 428:
VisiteSUIVI TEXTE SuiviDATE DATE Da
Page 429 and 430:
ObservanceDate d'entretien ou date
Page 431 and 432:
Mémoires et thèses réalisés à
Page 433 and 434:
Publications issues de la cohorte A
Page 435 and 436:
Page 437 and 438:
Page 439:
ird-00718213, version 1 - 16 Jul 20
show all

Bernard Taverne, Alice Desclaux, Papa Salif Sow

Create successful ePaper yourself

Delete template?

Save as template?